AU
UK
CA
NZ
IND
US
Last update at 2026-06-03T20:24:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants
Fri 16 May 25, 01:00 PMWondering what's happening in today's after-hours session?
Mon 07 Apr 25, 11:00 PM12 Most Profitable Pot Stocks Now
Wed 27 Dec 23, 11:37 PMWeekly Roundup on the Cannabis Sector & Psychedelic Sector
Mon 08 Aug 22, 11:00 AM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -19.97956M | -14.90391M | -8.16359M | -3.92928M | -2.86972M |
| Minority interest | - | - | - | - | - |
| Net income | -19.97956M | -15.02599M | -8.16091M | -4.65655M | -2.71840M |
| Selling general administrative | 10.01M | 7.43M | 3.44M | 1.78M | 1.90M |
| Selling and marketing expenses | 1.85M | 2.75M | 1.14M | 0.41M | 0.70M |
| Gross profit | 0.00000M | -0.00634M | 0.99M | 0.15M | 0.60M |
| Reconciled depreciation | 0.13M | 0.00000M | - | 0.04M | 0.04M |
| Ebit | -20.34232M | -14.77555M | -8.23934M | -4.18300M | -2.78466M |
| Ebitda | -20.21138M | -14.64093M | -8.23934M | -4.14645M | -2.74277M |
| Depreciation and amortization | 0.13M | 0.13M | 0.08M | 0.04M | 0.04M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -20.34232M | -14.77555M | -8.23934M | -4.18300M | -2.78466M |
| Other operating expenses | 20.34M | 14.78M | 10.14M | 4.75M | 3.97M |
| Interest expense | - | 0.00627M | 0.00268M | 0.00455M | 0.09M |
| Tax provision | 0.00000M | 0.00000M | 0.00000M | 0.00000M | -0.15132M |
| Interest income | 0.36M | 0.00912M | 0.00268M | 0.00455M | 0.00163M |
| Net interest income | 0.36M | 0.00912M | 0.00268M | 0.00455M | -0.08343M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | 0.12M | -0.00268M | 0.73M | -0.15132M |
| Total revenue | 0.00000M | 0.00000M | 1.90M | 0.60M | 1.18M |
| Total operating expenses | 20.34M | 14.77M | 9.22M | 4.30M | 3.38M |
| Cost of revenue | 0.00000M | 0.00634M | 0.91M | 0.45M | 0.58M |
| Total other income expense net | 0.36M | -0.12835M | 0.08M | 0.25M | -0.08507M |
| Discontinued operations | - | - | - | -0.76835M | -1.29220M |
| Net income from continuing ops | -19.97956M | -21.66551M | -8.16359M | -3.92928M | -2.71840M |
| Net income applicable to common shares | -19.97956M | -14.90391M | -11.37280M | -4.69764M | -2.71840M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 88.59M | 37.88M | 9.33M | 4.24M | 0.52M |
| Intangible assets | 52.72M | - | - | - | 0.05M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.04M | 0.06M | 0.04M | 0.03M | 0.03M |
| Total liab | 4.46M | 2.01M | 0.76M | 1.07M | 0.94M |
| Total stockholder equity | 84.13M | 35.87M | 8.57M | 3.16M | -0.41718M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.97M | 0.71M | 0.52M | 0.48M | 0.35M |
| Common stock | 150.84M | 86.59M | 45.94M | 34.19M | 26.95M |
| Capital stock | 150.84M | 125.87M | 45.94M | 34.19M | 26.95M |
| Retained earnings | -78.77447M | -58.79491M | -40.68179M | -32.51820M | -27.82057M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 33.36M | 37.50M | 9.12M | 3.60M | 0.09M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3.85M | 2.01M | 0.76M | 1.07M | 0.94M |
| Current deferred revenue | - | - | - | - | 0.15M |
| Net debt | -32.57648M | -37.50093M | -9.12362M | -3.60339M | -0.02833M |
| Short term debt | 0.17M | - | - | - | 0.07M |
| Short long term debt | - | - | - | - | 0.07M |
| Short long term debt total | 0.79M | - | - | - | 0.07M |
| Other stockholder equity | 12.06M | 8.08M | - | - | - |
| Property plant equipment | 1.19M | - | - | - | 0.09M |
| Total current assets | 34.69M | 37.88M | 9.33M | 4.24M | 0.38M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 31.41M | 35.87M | 8.57M | 3.16M | -0.46656M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.39M | 0.32M | 0.17M | 0.41M | 0.10M |
| Long term debt | - | - | - | - | - |
| Inventory | -0.10001M | - | - | 0.18M | 0.15M |
| Accounts payable | 2.71M | 1.30M | 0.23M | 0.59M | 0.38M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 12.06M | - | 3.32M | 1.49M | 0.45M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 53.90M | 0.00000M | 0.00000M | 0.00000M | 0.13M |
| Capital lease obligations | 0.79M | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -0.47687M | 0.00000M | 0.03M | 0.01M | -0.02444M |
| Change to liabilities | 1.56M | 1.11M | -0.29131M | 0.46M | -0.25745M |
| Total cashflows from investing activities | -0.47687M | -0.47687M | 0.03M | 0.01M | -0.02444M |
| Net borrowings | -0.05472M | -0.05472M | -0.05472M | -0.06500M | -0.13500M |
| Total cash from financing activities | 0.01M | 41.18M | 12.40M | 7.40M | 2.05M |
| Change to operating activities | -0.84799M | 0.21M | -0.10099M | -0.02729M | 0.03M |
| Net income | -19.97956M | -14.90391M | -8.16359M | -4.69764M | -2.71840M |
| Change in cash | -0.00414M | 28.38M | 5.52M | 3.51M | -0.13507M |
| Begin period cash flow | 0.04M | 9.12M | 3.60M | 0.09M | 0.23M |
| End period cash flow | 0.03M | 37.50M | 9.12M | 3.60M | 0.09M |
| Total cash from operating activities | -0.01609M | -12.80737M | -6.90978M | -3.90733M | -2.16043M |
| Issuance of capital stock | 0.01M | 59.87M | 12.40M | 7.47M | 2.18M |
| Depreciation | 0.13M | 0.13M | 0.13M | 0.13M | - |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | 0.00000M | 0.00000M | - | - | - |
| Change to inventory | - | 0.00000M | 0.18M | -0.03036M | 0.07M |
| Change to account receivables | 0.00724M | -0.09232M | 0.21M | -0.31548M | -0.04368M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | 0.05M | 0.03M | 0.03M | 0.01M | 0.07M |
| Change to netincome | 3.19M | 0.87M | 4.46M | 0.70M | 0.76M |
| Capital expenditures | 0.00030M | 0.48M | 0.48M | 0.48M | 0.02M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.72M | 1.23M | - | - | - |
| Stock based compensation | 3.19M | 1.46M | - | - | - |
| Other non cash items | 15.92M | -0.59439M | 8.16M | 4.70M | 2.72M |
| Free cash flow | -0.01639M | -12.80737M | -6.91028M | -3.90733M | -0.02444M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IXHL Incannex Healthcare Ltd ADR |
0.01 0.33% | 3.06 | - | - | 68.43 | 2.51 | 98.98 | -2.4351 |
| ZTS Zoetis Inc |
1.20 1.57% | 77.59 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
0.58 1.91% | 31.01 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 153.91 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| GALDY GALDERMA GROUP AG |
-0.79 1.89% | 40.92 | 74.21 | 41.67 | 8.64 | 5.55 | 9.15 | 42.22 |
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Hea
8 Century Circuit, Sydney, NSW, Australia, 2153
| Name | Title | Year Born |
|---|---|---|
| Mr. Joel Bradley Latham | MD, CEO & Exec. Director | 1990 |
| Mr. Madhukar Bhalla | CFO & Company Sec. | 1959 |
| Mr. Lekhram Changoer M.Sc. | Chief Technical Officer | 1967 |
| Dr. Mark Bleackley | Chief Scientific Officer, Head of Programs & Member of the Advisory Board | NA |
| Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. | Chief Exec. Officer of IncannexTM | NA |
| Ms. Rosemarie Walsh | VP of Clinical Operations & Member of the Advisory Board | NA |
| Mr. Joseph Swan | Head of Fin. | NA |
| Mr. Joel Bradley Latham | MD, CEO & Executive Director | 1990 |
| Mr. Joseph Swan | CFO, Treasurer & Secretary | 1992 |
| Mr. John Michailidis B.Sc., EMBA, M.A.I.C.D. | Chief Executive Officer of IncannexTM | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...